Webcast - Highlights from SABCS 2021

This accredited continuing education activity “Webcast - Highlights from SABCS 2021”, is recorded from the live webinar held on 1/29/2022. 

If you participated in the live conference titled - Highlights from SABCS 2021 on 1/29/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that conference held on 1/29/2021.  However, you may enroll in this activity to review the contents. 

Management of breast cancer is rapidly evolving. A number of potentially practice-changing abstracts are expected to be presented during the 2021 San Antonio Breast Cancer Symposium (SABCS 2021) in December, 2021. This webcast, a recording from the in-person oncology conference held in Seattle, Highlights from SABCS 2021, expert faculty will place abstract findings from the SABCS 2021 annual meeting into clinical context and discuss how the results may change the current standard of care for breast cancer patients. 

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, then you don't pay anything to register for this activity.

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting associated with this webcast and wish to register for this enduring material please contact us and we will register you for free.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Identify the role of novel molecular abnormalities, prognostic markers and risk factors in breast cancer pathogenesis, risk of recurrences and their implications on breast cancer prevention and management.
  • Review data presented at the 2021 San Antonio Breast Cancer Symposium and discuss their application in clinical settings 
  • Discuss the study design and primary endpoints of recently reported and ongoing clinical trials evaluating novel strategies for the management of breast cancer
  • Compare and contrast the safety and efficacy profiles of novel therapeutic strategies that impact breast cancer management
  • Integrate emerging evidence into treatment paradigms for treatment of patients with breast cancer
Course summary
Available credit: 
  • 5.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.
Course opens: 
02/09/2022
Course expires: 
02/09/2023
Cost:
$0.00

This educational activity features recorded videos from the live conference titled - Highlights from SABCS 2021.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.


Session 1

Moderator: Shaveta Vinayak, MD, MS

36 minutes: Advances and controversies in DCIS and locoregional invasive disease - Christos Vaklavas, MD
26 minutes: Prevention, survivorship, and healthcare delivery - Poorni Manohar, MD
38 minutes: Genetic and other biomarkers for prognosis and prediction of systemic therapy - Siddhartha Yadav, MBBS, MD


Session 2

Moderator: Natasha Hunter

27 minutes: Novel targets and therapeutics for early and advanced ER+ disease - Hannah Linden, MD
38 minutes: Advances in approaches to triple-negative breast cancer - Hope S. Rugo, MD
43 minutes: Q&A/Discussion - Nanette Robinson, MD


Session 3

Moderator: William R Gwin III, MD 

32 minutes: Updates in Radiation oncology - Janice Kim, MD
32 minutes: Updates in Breast surgery - Sara H. Javid, MD
40 minutes: HER2+ updates and leads for the future – (Neo)/Adjuvant and advanced settings - Jennifer M. Specht, MD
31 minutes: Q&A/Discussion - Fengting Yan, MD, PhD

 

DISCLOSURES 

No Members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity except for the following faculties: 

  • Shaveta Vinayak has a financial relationship (Grant Or Contract) with Seattle Genetics; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with PUMA; financial relationship (Grant Or Contract) with Oncosec.

  • Hope Rugo has a financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Roche ; financial relationship (Grant Or Contract) with Sermonix; financial relationship (Grant Or Contract) with Ayala; financial relationship (Professional Services) with NAPO; financial relationship (Grant Or Contract) with Lilly; financial relationship (Grant Or Contract) with Macrogenics; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Professional Services) with Samsung; financial relationship (Grant Or Contract) with Novartis; financial relationship (Grant Or Contract) with Seattle Genetics; financial relationship (Grant Or Contract) with Polyphor; financial relationship (Professional Services) with Puma; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Daiichi; financial relationship (Grant Or Contract) with Boehringer Ingelheim; financial relationship (Grant Or Contract) with Gilead.

  • Hannah Linden has a financial relationship (Grant or Contract) with zionexa, sanofi, eisai, and zentalis

All relevant financial relationships of individuals in control of the content have been identified and mitigated. 

DISCUSSION OF OFF LABEL PRODUCTS

If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved. 

 

Moderator(s)

William Gwin

has no relevant financial relationships to disclose at this time.
Speaker(s)

Nancy Davidson, MD

has no relevant financial relationships to disclose at this time.

Natasha Hunter, MD

has no relevant financial relationships to disclose at this time.

Sara Javid, MD

has no relevant financial relationships to disclose at this time.

Janice Kim, MD

has no relevant financial relationships to disclose at this time.

Poorni Manohar, MD

has no relevant financial relationships to disclose at this time.

Nanette Robinson, M.D.

has no relevant financial relationships to disclose at this time.

Hope Rugo

has a financial relationship (Grant Or Contract) with Polyphor;.
has a financial relationship (Professional Services) with Puma;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi;.
has a financial relationship (Grant Or Contract) with Sermonix;.
has a financial relationship (Grant Or Contract) with Ayala;.
has a financial relationship (Professional Services) with NAPO;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Roche ;.
has a financial relationship (Grant Or Contract) with Macrogenics;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Samsung;.
has a financial relationship (Grant Or Contract) with Lilly;.

Jennifer Specht, MD

has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor

has no relevant financial relationships to disclose at this time.

Shaveta Vinayak, MD, MS

has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with PUMA;.
has a financial relationship (Grant Or Contract) with Oncosec;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity has been supported with an independent medical education grant from the following companies:

  • Pfizer, Inc.

Important Information about Claiming CME for this activity:

AVAILABLE CREDIT

5.50 ABIM MOC II

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
image

5.50 AMA PRA Category 1 Credit™

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this enduring activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

5.50 Nursing Contact Hours

Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.

Available Credit

  • 5.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.50 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you have started watching the recorded content.